Claim Missing Document
Check
Articles

Found 2 Documents
Search

Isolasi dan Identifikasi Senyawa Metabolit Sekunder Ekstrak Daun Kopi Arabika (Coffea arabica) Menggunakan Teknik Kromatografi Nurul Amaliya Hikma; A. Nur Afiah Rahman; Siti Aisyah Basir; A. Yeyen Maharani; Pingki Pingki; A. Putri Wulandari Syam; Mufidah Humairah S; Nur Andini; Fatma Fatma; Fityatun Usman
Inovasi Kesehatan Global Vol. 2 No. 3 (2025): Agustus : Inovasi Kesehatan Global
Publisher : Lembaga Pengembangan Kinerja Dosen

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.62383/ikg.v2i3.2216

Abstract

This study aims to extract and purify secondary metabolite compounds from Coffea arabica leaves using various separation techniques, such as maceration, column chromatography, thin layer chromatography (KLT), and preparatory KLT, and followed by flavonoid content analysis using UV-Vis spectrophotometry. The process begins with drying the arabica coffee leaves, then extraction is carried out using 96% ethanol for three days. After that, the solvent is evaporated with a rotary evaporator at 60°C to obtain a viscous extract. The extracts were further separated using column chromatography with a mixed solvent of n-hexane: ethyl acetate (3:1), resulting in 12 fractions that showed color differences, which was an indication of the diversity of the compounds in the extract. Advanced identification was carried out with KLT using methanol solvents: chloroform (9:1) at UV wavelengths of 254 nm and 366 nm, indicating the presence of compounds with medium to high polarity. Furthermore, the isolated compounds were further separated using the preparative KLT (KLTP) method. To determine the flavonoid content, UV-Vis spectrophotometry was performed at a wavelength of 431 nm, using quercetin as standard. The results of the analysis showed that Arabica coffee leaf extract had a yield of 7.35% and a total flavonoid content of 19.0605 mgQE/g. These findings show that arabica coffee leaves are a source of flavonoid compounds that have the potential for the development of herbal or phytopharmaceutical products. The flavonoid content found may provide health benefits, particularly in increasing antioxidant activity, which can be used in the treatment of oxidative stress-related diseases. The results of this study also open up opportunities for the development of plant-based products, especially Arabica coffee, in the pharmaceutical and cosmetic industries as an efficacious natural active ingredient.
Luaran Klinis Pasien Covid-19 Yang Menerima Remdesivir Berdasarkan Derajat Keparahan Penyakit Andi Utari Prasetya Ningrum; Nurul Amalia Fadilah; Zulkifli; Andi Ulfah Magefirah Rasyid; Fityatun Usman; Nurfadilah; Widya Hardiyanti
Media Farmasi Vol 22 No 1 (2026): Media Farmasi Edisi April 2026
Publisher : Jurusan Farmasi Poltekkes kemenkes Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32382/mf.v22i1.1568

Abstract

Coronavirus Disease 2019 (COVID-19) remains a global concern even though the international emergency status has been lifted. The resurgence of cases in several regions and the emergence of new variants indicate that this disease still has the potential to cause another wave of infections. This study aims to determine the relationship between the severity of COVID-19 and clinical outcomes in patients receiving remdesivir therapy. This study aims to determine the relationship between the severity of COVID-19 and clinical outcomes in patients receiving remdesivir therapy. This study is an observational study with a cross-sectional design using secondary data from medical records of hospitalized COVID-19 patients receiving remdesivir therapy. Clinical outcomes were determined by assessing the improvement in the patient's clinical condition, length of hospitalization, and mortality in patients. Analysis was performed using the chi-square test to examine the relationship between severity and clinical outcomes. The results showed that patients with mild and moderate severity had a higher rate of clinical improvement than severe/critical patients (100%, 94.9% vs 59.4%; p<0.001). Length of hospitalization was also shorter in mild and moderate patients compared to severe/critical, with the proportion of stays ≤14 days of 100%, 92.4%, and 69.5%, respectively (p<0.001). In addition, the mortality rate was higher in severe/critical patients at 41.6%, while in mild and moderate patients the proportion of patients who did not experience death was higher (100% and 96.6%; p<0.001). This study concluded that disease severity was closely related to the clinical outcomes of COVID-19 patients receiving remdesivir therapy, where the effectiveness of therapy was higher in patients with mild to moderate conditions.